Safety Profile of Pertuzumab With Trastuzumab and Docetaxel in Patients From Asia With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Results From the Phase III Trial CLEOPATRA

INTRODUCTION. We report detailed safety analyses by geographic region from the phase III study CLEOPATRA with pertuzumab, trastuzumab, and docetaxel in patients with human epidermal growth factor receptor 2 (HER2)-positive first-line metastatic breast cancer. PATIENTS AND METHODS. Patients received...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Swain, Sandra M., Im, Young-Hyuck, Im, Seock-Ah, Chan, Valorie, Miles, David, Knott, Adam, Clark, Emma, Ross, Graham, Baselga, José
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: AlphaMed Press 2014
Aiheet:
Breast Cancer
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4077449/
https://ncbi.nlm.nih.gov/pubmed/24869931
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0033
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia